#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Martin Stogniew Email
Chief Development Officer . Transcend Therapeutics
How to contact Martin Stogniew
Join and see Martin's contact info for free!Current Roles
Employees:
26Revenue:
$2MAbout
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications. Transcend's leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. We are backed by AlleyCorp, an incubator and venture capital fund that has founded some of the most transformative companies in New York, including MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, and many others. AlleyCorp incubations have collectively raised $1B+ in venture capital with an aggregate value of $30B+. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.Transcend Therapeutics Address
220 5th AveNew York, NY